Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

Part of paid clinical trials in Santa Monica, California.

Sponsor
Orrin M Troum, M.D. and Medical Associates
Study ID
NCT01333878
Phase
PHASE2/PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Subcutaneous Abatacept — BIOLOGICAL
    Subcutaneous Abatacept 125 mg once weekly for 6 months

Study Details

The hypothesis of this study is that subcutaneous Abatacept is effective in reducing synovial inflammation, osteitis, and erosions in Rheumatoid Arthritis as assessed by low field extremity MRI and X-ray.

Key Dates

First listed
Apr 12, 2011
Start date
Mar 31, 2011
Status verified
Apr 2014
Primary completion
Nov 30, 2013
Completion
Jan 31, 2014

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-Label Subcutaneous Abatacept
    Open-Label Subcutaneous Abatacept

Primary Outcome Measure

Inhibition & progression of structural damage [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Orrin M. Troum, MD and Medical AssociatesSanta MonicaCalifornia90404-

Find similar trials in Santa Monica, CA

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials
By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
Orrin M. Troum, MD and Medical Associates· Santa Monica, CA

Related Studies